Abstract | OBJECTIVE: To present an overview of antisense technology and to review and assess available literature on the chemistry, pharmacology, pharmacokinetics, drug interactions, preclinical and clinical studies, dosing, and adverse events of ISIS 301012 in the treatment of hyperlipidemia. DATA SOURCES: STUDY SELECTION AND DATA EXTRACTION: Available English-language literature, including abstracts, preclinical, and clinical trials, review articles, and scientific presentations were examined. DATA SYNTHESIS: CONCLUSIONS:
ISIS 301012 is the first agent to enter clinical trials utilizing an antisense mechanism for reducing the production of apolipoprotein B. Further studies are needed to verify its safety, efficacy, and position of therapy in the dyslipidemic patient.
|
Authors | Matthew K Ito |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 41
Issue 10
Pg. 1669-78
(Oct 2007)
ISSN: 1542-6270 [Electronic] United States |
PMID | 17848425
(Publication Type: Journal Article, Review)
|
Chemical References |
- Apolipoprotein B-100
- Drugs, Investigational
- Oligonucleotides
- Oligonucleotides, Antisense
- mipomersen
|
Topics |
- Animals
- Apolipoprotein B-100
(antagonists & inhibitors)
- Drugs, Investigational
(administration & dosage, chemistry)
- Genetic Therapy
(methods, trends)
- Humans
- Hypercholesterolemia
(blood, genetics, therapy)
- Oligonucleotides
(administration & dosage, chemistry, genetics)
- Oligonucleotides, Antisense
(administration & dosage, chemistry, genetics)
|